{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:08:47Z","timestamp":1777284527350,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T00:00:00Z","timestamp":1397779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1245\/s10434-014-3606-9","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T22:40:16Z","timestamp":1397688016000},"page":"2517-2524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44)"],"prefix":"10.1245","volume":"21","author":[{"given":"Bernd","family":"Gerber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunter","family":"von Minckwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Eidtmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holm","family":"Eggemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kornelia","family":"Kittel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Hanusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Solbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jackisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maik","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Nekljudova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,18]]},"reference":[{"key":"3606_CR1","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1073\/pnas.0409462102","volume":"102","author":"HY Chang","year":"2005","unstructured":"Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005;102:3738\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3606_CR2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","volume":"366","author":"G Minckwitz von","year":"2012","unstructured":"von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366:299\u2013309.","journal-title":"N Engl J Med"},{"issue":"12","key":"3606_CR3","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/annonc\/mdt361","volume":"24","author":"B Gerber","year":"2013","unstructured":"Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthrcycline-taxane based chemotherapy in 678 triple negative primary breast cancers; results from the GEPARQUINTO study (GBG 44). Ann Oncol. 2013;24(12):2978\u201384. doi: 10.1093\/annonc\/mdt361 .","journal-title":"Ann Oncol"},{"key":"3606_CR4","doi-asserted-by":"crossref","unstructured":"Makhoul I, Klimberg VS, Korourian S, et al. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer. Am J Clin Oncol. 2013. doi: 10.1097\/COC.0b013e31828940c3 .","DOI":"10.1097\/COC.0b013e31828940c3"},{"key":"3606_CR5","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039\u201345.","journal-title":"J Clin Oncol"},{"key":"3606_CR6","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","journal-title":"N Engl J Med"},{"key":"3606_CR7","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103\u201311.","journal-title":"Lancet"},{"key":"3606_CR8","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539\u201344.","journal-title":"J Clin Oncol"},{"key":"3606_CR9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","volume":"91","author":"FA Scappaticci","year":"2005","unstructured":"Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91:173\u201380.","journal-title":"J Surg Oncol"},{"key":"3606_CR10","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697\u2013705.","journal-title":"J Clin Oncol"},{"key":"3606_CR11","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med"},{"key":"3606_CR12","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/annonc\/mdr463","volume":"23","author":"M Reck","year":"2012","unstructured":"Reck M, Barlesi F, Crin\u00f2 L, et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol. 2012;23:1111\u201320.","journal-title":"Ann Oncol"},{"key":"3606_CR13","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227\u201334.","journal-title":"J Clin Oncol"},{"key":"3606_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mds590","volume":"24","author":"JC Soria","year":"2013","unstructured":"Soria JC, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomised, phase II\/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24:20\u201330.","journal-title":"Ann Oncol"},{"key":"3606_CR15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/annonc\/mdq430","volume":"22","author":"IE Smith","year":"2011","unstructured":"Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol. 2011;22:595\u2013602.","journal-title":"Ann Oncol"},{"key":"3606_CR16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.2005.03.4645","volume":"24","author":"SB Wedam","year":"2006","unstructured":"Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769\u201377.","journal-title":"J Clin Oncol"},{"key":"3606_CR17","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/CAD.0b013e328349c7bb","volume":"22","author":"I Kriegel","year":"2011","unstructured":"Kriegel I, Cottu PH, Fourchotte V, et al. Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy. Anticancer Drugs. 2011;22:1020\u20133.","journal-title":"Anticancer Drugs"},{"key":"3606_CR18","doi-asserted-by":"crossref","unstructured":"Cottu PH, Fourchotte V, Vincent-Salomon A, Kriegel I, Fromantin I. Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy. J Wound Care. 2011;20:403\u20134, 406, 408.","DOI":"10.12968\/jowc.2011.20.9.403"},{"key":"3606_CR19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s10637-010-9505-4","volume":"29","author":"E Lecarpentier","year":"2011","unstructured":"Lecarpentier E, Ouaffi L, Mir O, et al. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. Invest New Drugs. 2011;29:1500\u20133.","journal-title":"Invest New Drugs"},{"key":"3606_CR20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00266-010-9535-5","volume":"34","author":"V Lazzati","year":"2010","unstructured":"Lazzati V, Zygon J, Lohsiriwat V, Veronesi P, Petit JY. Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab. Aesthetic Plast Surg. 2010;34:796\u20137.","journal-title":"Aesthetic Plast Surg"},{"key":"3606_CR21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1055\/s-0028-1098701","volume":"134","author":"R Kube","year":"2009","unstructured":"Kube R, Meyer F, Bien N, et al. Surgical management of bevacizumab-associated peritonitis due to perforation. Zentralbl Chir. 2009;134:462\u20137.","journal-title":"Zentralbl Chir"},{"key":"3606_CR22","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/annonc\/mds658","volume":"24","author":"HR Kim","year":"2013","unstructured":"Kim HR, Jung KH, Im SA, et al. Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). Ann Oncol. 2013;24:1485\u201390.","journal-title":"Ann Oncol"},{"key":"3606_CR23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jnci\/92.2.143","volume":"92","author":"CY Li","year":"2000","unstructured":"Li CY, Shan S, Huang Q, et al. Initial stages of tumor cell\u2013induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst. 2000;92:143\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"3606_CR24","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ejca.2013.02.027","volume":"49","author":"J Huober","year":"2013","unstructured":"Huober J, Fasching PA, Hanusch C, et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin\/cyclophosphamide (EC) +\/\u2212 bevacizumab\u2014results of the randomised GeparQuinto study (GBG 44). Eur J Cancer. 2013;49:2284\u201393.","journal-title":"Eur J Cancer"},{"key":"3606_CR25","doi-asserted-by":"crossref","unstructured":"Bear HD, Tang G, Rastogi P, et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Res. 2011. doi: 10.1158\/0008-5472.SABCS11-PD07-08 .","DOI":"10.1158\/0008-5472.SABCS11-PD07-08"},{"key":"3606_CR26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1245\/s10434-010-1366-8","volume":"18","author":"M Golshan","year":"2011","unstructured":"Golshan M, Garber JE, Gelman R, et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol. 2011;18:733\u20137.","journal-title":"Ann Surg Oncol"},{"key":"3606_CR27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","volume":"62","author":"CR Gordon","year":"2009","unstructured":"Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62:707\u20139.","journal-title":"Ann Plast Surg"},{"key":"3606_CR28","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/cncr.25573","volume":"117","author":"JP Erinjeri","year":"2011","unstructured":"Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, Solomon SB. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117:1296\u2013301.","journal-title":"Cancer"},{"key":"3606_CR29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejca.2011.11.021","volume":"48","author":"J Cortes","year":"2012","unstructured":"Cortes J, Caralt M, Delaloge S, et al. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer. 2012;48:475\u201381.","journal-title":"Eur J Cancer"},{"key":"3606_CR30","unstructured":"NCI. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm . Accessed 5 Nov 2013."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3606-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-014-3606-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3606-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T11:24:22Z","timestamp":1559647462000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-014-3606-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,18]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["3606"],"URL":"https:\/\/doi.org\/10.1245\/s10434-014-3606-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,18]]}}}